RxDoctor Payments Data

Selena McNeill

Family · Lumberton, NCNPI 1548828106

Payments from drug & device makers

$660in general payments, 2019–2025

Across 36 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$191
  • Nestle Healthcare Nutrition Inc.$102
  • Grifols USA, LLC$67
  • Corcept Therapeutics$46
  • Esperion Therapeutics, Inc.$38
  • Gilead$33
  • plus $184 from 11 others

What the payments were for

  • Food & beverage$660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$660 in reported general payments places this provider in the 60th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$269
Medicare patients
12
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin31$44,293
TrulicityDulaglutide41$43,397
OzempicSemaglutide33$43,112
LinzessLinaclotide61$41,156
MounjaroTirzepatide37$39,346
EliquisApixaban29$35,201
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$20,113
JanumetSitagliptin Phos/Metformin Hcl27$19,465
RybelsusSemaglutide14$19,042
EntrestoSacubitril/Valsartan18$17,742
GlyxambiEmpagliflozin/Linagliptin12$7,359
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$7,200
Dexlansoprazole DrDexlansoprazole18$6,393
BrilintaTicagrelor14$6,366
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$5,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$16$82,74378 claims
Novo NordiskOzempic, Rybelsus$191$62,15447 claims
AbbVieLinzess$15$41,15661 claims
GSKTrelegy Ellipta$12$20,11319 claims
MerckJanumet$20$19,46527 claims
AstraZenecaBrilinta, Symbicort$18$12,02534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,522 family providers in North Carolina.

Other family in Lumberton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →